Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

Clinical trial NCT06867536 · RECRUITING

Trial details

NCT number: NCT06867536
Sponsor: Liling Zhang
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Lymphoma

Start date: 2025-04-01
Primary completion: 2028-08-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.